Effect of short course chemotherapy on salivary paracetamol elimination. 1988

K Madhusudanarao, and J S Bapna, and C Adithan, and K Ray, and N Venkatadri, and G L Kamatchi, and M L Seetharaman, and P Bahadur
Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education & Research, Pondicherry, India.

1. Salivary elimination of paracetamol was studied in six male pulmonary tuberculosis patients on short course chemotherapy. 2. Peak paracetamol concentration showed a steady decrease at the end of first week and continued until the end of the study. 3. The elimination half-life of paracetamol decreased 5 weeks after the therapy with a corresponding increase in the clearance rate. 4. Adjustment of dosage of drugs that are metabolized by the microsomal enzymes may be required in patients on anti-tubercular drug regimen in which rifampicin is included.

UI MeSH Term Description Entries
D008297 Male Males
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000082 Acetaminophen Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage. Acetamidophenol,Hydroxyacetanilide,Paracetamol,APAP,Acamol,Acephen,Acetaco,Acetominophen,Algotropyl,Anacin-3,Datril,N-(4-Hydroxyphenyl)acetanilide,N-Acetyl-p-aminophenol,Panadol,Tylenol,p-Acetamidophenol,p-Hydroxyacetanilide,Anacin 3,Anacin3
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D012463 Saliva The clear, viscous fluid secreted by the SALIVARY GLANDS and mucous glands of the mouth. It contains MUCINS, water, organic salts, and ptylin. Salivas
D014397 Tuberculosis, Pulmonary MYCOBACTERIUM infections of the lung. Pulmonary Consumption,Pulmonary Phthisis,Pulmonary Tuberculoses,Pulmonary Tuberculosis,Tuberculoses, Pulmonary,Consumption, Pulmonary,Consumptions, Pulmonary,Phthises, Pulmonary,Phthisis, Pulmonary,Pulmonary Consumptions,Pulmonary Phthises

Related Publications

K Madhusudanarao, and J S Bapna, and C Adithan, and K Ray, and N Venkatadri, and G L Kamatchi, and M L Seetharaman, and P Bahadur
August 1985, British journal of clinical pharmacology,
K Madhusudanarao, and J S Bapna, and C Adithan, and K Ray, and N Venkatadri, and G L Kamatchi, and M L Seetharaman, and P Bahadur
June 1988, Clinical and experimental pharmacology & physiology,
K Madhusudanarao, and J S Bapna, and C Adithan, and K Ray, and N Venkatadri, and G L Kamatchi, and M L Seetharaman, and P Bahadur
January 1986, European journal of clinical pharmacology,
K Madhusudanarao, and J S Bapna, and C Adithan, and K Ray, and N Venkatadri, and G L Kamatchi, and M L Seetharaman, and P Bahadur
January 1993, Indian journal of physiology and pharmacology,
K Madhusudanarao, and J S Bapna, and C Adithan, and K Ray, and N Venkatadri, and G L Kamatchi, and M L Seetharaman, and P Bahadur
March 1987, British journal of clinical pharmacology,
K Madhusudanarao, and J S Bapna, and C Adithan, and K Ray, and N Venkatadri, and G L Kamatchi, and M L Seetharaman, and P Bahadur
September 1987, Clinical and experimental pharmacology & physiology,
K Madhusudanarao, and J S Bapna, and C Adithan, and K Ray, and N Venkatadri, and G L Kamatchi, and M L Seetharaman, and P Bahadur
October 1980, The American review of respiratory disease,
K Madhusudanarao, and J S Bapna, and C Adithan, and K Ray, and N Venkatadri, and G L Kamatchi, and M L Seetharaman, and P Bahadur
November 1982, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
K Madhusudanarao, and J S Bapna, and C Adithan, and K Ray, and N Venkatadri, and G L Kamatchi, and M L Seetharaman, and P Bahadur
December 1981, Chest,
K Madhusudanarao, and J S Bapna, and C Adithan, and K Ray, and N Venkatadri, and G L Kamatchi, and M L Seetharaman, and P Bahadur
December 1979, The Medical journal of Australia,
Copied contents to your clipboard!